Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04690322 · ClinicalTrials.gov registry record · Phase 4
POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies
A Phase 4 study of Hemophilia A and Factor VIII, sponsored by University of Texas Southwestern Medical Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT04690322: Recruiting Phase 4 study of Hemophilia A and Factor VIII, sponsored by University of Texas Southwestern Medical Center.
NCT04690322 is a Phase 4 study of Hemophilia A and Factor VIII that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 28 participants, below the 91-participant average among 42 other Hemophilia A trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04690322, a Phase 4 study of Hemophilia A and Factor VIII, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, randomized control trial in which each patient will be randomly assigned to receive either extended half-life factor VIII based replacement therapy or non-FVIII based replacement therapy, which are both standard of care treatment for persons with Hemophilia A.
Conditions Studied
Interventions
- DRUG Emicizumab
- DRUG Eloctate
- DRUG Adynovate
Study Locations (1)
Texas
- The University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2021-04-15 |
| Est. Completion | 2027-07 |
| Phase | Phase 4 |
What NCT04690322 shows while recruiting
NCT04690322 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 91-participant average among 42 other Hemophilia A trials with a reported enrollment target (69% lower).
The record links to 2 conditions, with Hemophilia A appearing as the primary indexed condition, and to 3 interventions - of which Emicizumab is the first listed.
NCT04690322 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04690322 about?
NCT04690322 is a clinical study titled "POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies". This is a prospective, randomized control trial in which each patient will be randomly assigned to receive either extended half-life factor VIII based replacement therapy or non-FVIII based replacement therapy, which are both standard of care treatment for persons with Hemophilia A.
What is the current status of trial NCT04690322?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2021-04-15. Estimated completion is 2027-07.
What conditions does trial NCT04690322 study?
This clinical trial studies the following conditions: Hemophilia A, Factor VIII.
What interventions are being tested in trial NCT04690322?
The interventions under investigation include: Emicizumab (DRUG), Eloctate (DRUG), Adynovate (DRUG).
Who is sponsoring clinical trial NCT04690322?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04690322 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04690322's enrollment target sits among peer trials
28 27th of 42 higher than 15 of 42 other Hemophilia A trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hemophilia A trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
RECRUITING · Phase 4
-
A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
RECRUITING · Phase 4
-
Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies
COMPLETED · Phase 4
-
Prophylaxis Regimen for Hemophilia A Patients
COMPLETED · Phase 4
-
Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery
COMPLETED · Phase 4
-
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI